0. DOCID:28058 SCORE: 0.000250012882140227
DOCNO: 12565007
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: trends
QUALIFIER: therapeutic use
QUALIFIER: therapeutic use
AUTHOR: Andrew D Westwell AD
AFFILIATION: School of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham, UK NG7 2RD. Andrew.Westwell@nottingham.ac.uk
PUBTYPE: Journal Article
JOURNALTITLE: Drug discovery today.
COUNTRY: England
TITLE: A new era in cancer therapeutics?
PUBDATE: 20030101
Highlights from the 14th EORTC-NCI-AACR Symposium Molecular Targets and Cancer Therapeutics, 19-22 November 2002, in Frankfurt, Germany.


1. DOCID:28555 SCORE: 0.000250012714172963
DOCNO: 16121704
OWNER: NLM
STATUS: In-Process
AUTHOR: Tomasz Switaj T
AUTHOR: Witold Lasek W
AFFILIATION: Center of Oncology--Institute Soft Tissue/Bone Sarcoma and Melanoma Department, Roentgena 5, Warsaw 02-781, Poland. tswitaj@ib.amwaw.edu.pl
PUBTYPE: Journal Article
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Technology evaluation: HYB-2055, Hybridon.
PUBDATE: 20050801
Hybridon is developing immunomodulatory oligonucleotides. including injectable HYB-2055 (IMOxine) which acts as an agonist of toll-like receptor 9, for the potential treatment of cancer. HYB-2055 is currently undergoing phase II clinical trials. The immunomodulatory oligonucleotides are also being investigated for the potential treatment of infectious diseases and immune disorders.


2. DOCID:28300 SCORE: 0.00025001106659379
DOCNO: 15157868
AUTHOR: Anthony C Bishop AC
AFFILIATION: Amherst College, Department of Chemistry, Amherst, MA 01002 USA.
PUBTYPE: Comment
PUBTYPE: Journal Article
JOURNALTITLE: Chemistry & biology.
COUNTRY: England
TITLE: A hot spot for protein kinase inhibitor sensitivity.
PUBDATE: 20040501
ATP binding site-directed protein kinase inhibitors are potent weapons in the war on cancer. However, specific mutations at an inhibitor-sensitivity "hot spot" can render these molecules ineffective. In this issue of Chemistry & Biology, Daub and coworkers have used an array of known kinase inhibitors to systematically characterize the desensitizing effects of hot spot mutations.


3. DOCID:29137 SCORE: 0.00025000941623339
DOCNO: 14998484
AUTHOR: Joachim Kienast J
AUTHOR: Wolfgang E Berdel WE
AFFILIATION: Department of Medicine, Hematology and Oncology, University of Muenster, D-48129 Muenster, Germany. kienast@uni-muenster.de
PUBTYPE: Comment
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer cell.
COUNTRY: United States
TITLE: c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions.
PUBDATE: 20040201
Gene expression profiling studies reported by Hurt et al. in this issue of Cancer Cell reveal an unexpectedly frequent overexpression of c-maf in multiple myeloma and identify molecular targets of c-maf transactivation. The results define c-maf as a prototype of a class of oncogenes that not only stimulate cell cycle progression, but also promote pathological interactions between tumor and stroma cells.


4. DOCID:28292 SCORE: 0.000250009415420897
DOCNO: 16109367
AUTHOR: Peter K Vogt PK
AUTHOR: Andreas G Bader AG
AFFILIATION: Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.
PUBTYPE: Comment
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Molecular cell.
COUNTRY: United States
TITLE: Jun: stealth, stability, and transformation.
PUBDATE: 20050801
A recent paper by Wei and collaborators in Cancer Cell sheds light on the effects of one of the mutations in v-Jun and has broad implications for our understanding of control mechanisms that direct the timing of important cell cycle functions (Wei et al., 2005).


5. DOCID:28000 SCORE: 0.000250008504178959
DOCNO: 11179497
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: analogs & derivatives
AUTHOR: A J Weiss AJ
AUTHOR: R D Lackman RD
AFFILIATION: Department of Medicine, Allegheny General University School of Medicine, Philadelphia, PA 19107, USA.
PUBTYPE: Journal Article
JOURNALTITLE: International journal of oncology.
COUNTRY: Greece
TITLE: Concurrent administration of vinorelbine with human recombinant granulocyte-macrocyte stimulating factor.
PUBDATE: 20010301
Thirty-three patients with incurable neoplasms resistant to standard therapy received vinorelbine 10 mg/m(2)/day by continuous infusion with concurrent administration of rHGM-CSF 4 microg/m(2)/day. The duration of the vinorelbine infusion was individualized; the infusion was continued until early evidence of hematopoietic toxicity was noted. The concurrent administration of GM-CSF permitted a substantial increase in dose intensity of the anti-cancer agent without a corresponding increase in drug toxicity. There was no evidence that the anti-tumor effect of vinorelbine was compromised by the concurrent administration of GM-CSF.


6. DOCID:30841 SCORE: 0.0002500082000254
DOCNO: 14608562
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: pathology
QUALIFIER: complications
QUALIFIER: therapy
AUTHOR: Nancy Stephenson N
AUTHOR: Jo Ann Dalton JA
AUTHOR: John Carlson J
AFFILIATION: East Carolina School of Nursing, Greenville, NC 27858-4353, USA. stephensonn@mail.ecu.edu
PUBTYPE: Clinical Trial
PUBTYPE: Journal Article
JOURNALTITLE: Applied nursing research : ANR.
COUNTRY: United States
TITLE: The effect of foot reflexology on pain in patients with metastatic cancer.
PUBDATE: 20031101
Thirty-six oncology inpatients participated in this third pilot study investigating the effects of foot reflexology in which equianalgesic dosing was calculated. Foot reflexology was found to have a positive immediate effect for patients with metastatic cancer who report pain, although there was no statistically significant effect at 3 hours after intervention or at 24 hours after intervention. Further study is suggested for foot reflexology delivered by family in the homes for management of cancer pain.


7. DOCID:28105 SCORE: 0.000250008177869346
DOCNO: 11995271
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: Frank Lee F
AUTHOR: Hitendra R H Patel HR
AFFILIATION: Institute of Urology and Nephrology, University College London, London W1W 7EY.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Hospital medicine (London, England : 1998)
COUNTRY: England
TITLE: Kidney cancer: current management guidelines.
PUBDATE: 20020401
Renal cell carcinoma accounts for 2% of all cancers. Medical progress has improved the outcome of early but not advanced disease. This article highlights the current practice for the management of renal cell carcinoma.


8. DOCID:28472 SCORE: 0.000250008159182011
DOCNO: 15278142
OWNER: NLM
STATUS: PubMed-not-MEDLINE
QUALIFIER: chemistry
QUALIFIER: antagonists & inhibitors
QUALIFIER: chemistry
QUALIFIER: chemistry
QUALIFIER: antagonists & inhibitors
AUTHOR: Carine Aubry C
AUTHOR: Paul R Jenkins PR
AUTHOR: Sachin Mahale S
AUTHOR: Bhabatosh Chaudhuri B
AUTHOR: Jean-Didier Maréchal JD
AUTHOR: Michael J Sutcliffe MJ
AFFILIATION: Department of Chemistry, University of Leicester, Leicester LE1 7RH, UK. kin@le.ac.uk
PUBTYPE: Journal Article
JOURNALTITLE: Chemical communications (Cambridge, England)
COUNTRY: England
TITLE: New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
PUBDATE: 20040801
The first biologically active non-planar analogues of the toxic anti-cancer agent, fascaplysin, have been produced; we present the design, synthesis and biological activity of three tryptamine derivatives.


9. DOCID:28194 SCORE: 0.000250007879090739
DOCNO: 12431032
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pharmacology
QUALIFIER: pharmacology
QUALIFIER: pharmacology
AUTHOR: Gerhard Ecker G
AFFILIATION: Institute of Pharmaceutical Chemistry, University of Vienna, Austria. Gerhard.F.Ecker@univie.ac.at
PUBTYPE: Journal Article
JOURNALTITLE: Current opinion in investigational drugs (London, England : 2000)
COUNTRY: England
TITLE: Troxacitabine (Shire Pharmaceuticals).
PUBDATE: 20021001
Shire Pharmaceuticals (formerly BioChem Pharma) is developing troxacitabine (Troxatyl), a novel dioxolane nucleoside analog, as a potential treatment for acute myeloid leukemia (AML), pancreatic cancer and solid tumors. Phase I and II clinical studies in patients with pancreatic cancer and AML are in progress.


10. DOCID:31570 SCORE: 0.000250007702561051
DOCNO: 12407699
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Acid Anhydride Hydrolases
DESCRIPTOR: Cytogenetics
QUALIFIER: genetics
AUTHOR: Yasuhiro Mitsuuchi Y
AUTHOR: Joseph R Testa JR
AFFILIATION: Fox Chase Cancer Center in Philadelphia, Pennsylvania 19111, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: American journal of medical genetics.
COUNTRY: United States
TITLE: Cytogenetics and molecular genetics of lung cancer.
PUBDATE: 20021001
The development and progression of lung cancer is a multistep process characterized by the accumulation of numerous genetic and epigenetic alterations, some of which occur early in the course of disease. In this review, we summarize cytogenetic imbalances and molecular genetic/epigenetic changes seen in human small-cell and non-small-cell lung cancer. Alterations of tumor suppressor genes and oncogenes leading to perturbations of key cell-regulatory and growth-control pathways are highlighted. The translational implications of molecular biomarkers for risk assessment, early detection, and monitoring of chemoprevention trials are discussed.


11. DOCID:28988 SCORE: 0.000250007583405855
DOCNO: 16266975
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: biosynthesis
QUALIFIER: metabolism
AUTHOR: Patrice J Morin PJ
AFFILIATION: Laboratory of Cellular and Molecular Biology, National Institute on Aging, NIH, Baltimore, Maryland 21224, USA. Morinp@grc.nia.nih.gov
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cancer research.
COUNTRY: United States
TITLE: Claudin proteins in human cancer: promising new targets for diagnosis and therapy.
PUBDATE: 20051101
The tight junction proteins claudins are abnormally regulated in several human cancers. In particular, claudin-3 and claudin-4 are frequently overexpressed in several neoplasias, including ovarian, breast, pancreatic, and prostate cancers. Although the exact roles of these proteins in tumorigenesis are still being uncovered, it is clear that they represent promising targets for cancer detection, diagnosis, and therapy.


12. DOCID:30258 SCORE: 0.000250007498437857
DOCNO: 15686629
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: secondary
QUALIFIER: anatomy & histology
QUALIFIER: pathology
AUTHOR: Juan Juan Yin JJ
AUTHOR: Claire B Pollock CB
AUTHOR: Kathleen Kelly K
AFFILIATION: Cell and Cancer Biology Branch, NCI, NIH, Bethesda, MD 20892, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Cell research.
COUNTRY: England
TITLE: Mechanisms of cancer metastasis to the bone.
PUBDATE: 20050101
Some of the most common human cancers, including breast cancer, prostate cancer, and lung cancer, metastasize with avidity to bone. What is the basis for their preferential growth within the bone microenvironment? Bidirectional interactions between tumor cells and cells that make up bone result in a selective advantage for tumor growth and can lead to bone destruction or new bone matrix deposition. This review discusses our current understanding of the molecular components and mechanisms that are responsible for those interactions.


13. DOCID:28179 SCORE: 0.000250007221502807
DOCNO: 12477647
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Bladder Neoplasms
AUTHOR: Dominique K Chopin DK
AUTHOR: Bernard Gattegno B
AFFILIATION: Department of Urology, Henri Mondor Hospital, Créteil, France.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: European urology.
COUNTRY: Netherlands
TITLE: Superficial bladder tumors.
PUBDATE: 20021201
This article is a summary of the 2001 French Urological Association (AFU) report on superficial bladder cancer. Major topics include histopathological classification, risk categories, natural history of the disease, standard treatments, the impact of molecular biology on clinical practice, the place of cystectomy, and modalities of intravesical instillations.


14. DOCID:28182 SCORE: 0.000250007221502807
DOCNO: 16399896
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: HSP70 Heat-Shock Proteins
QUALIFIER: physiology
AUTHOR: Ezra V Pierpaoli EV
AFFILIATION: Chemin du Verger 16, 1752 Villars-sur-Glâne, Switzerland. epierpaoli@hotmail.com
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Annals of the New York Academy of Sciences.
COUNTRY: United States
TITLE: The role of Hsp70 in age-related diseases and the prevention of cancer.
PUBDATE: 20051201
This article focuses on the structure, function, mode of action of one of the major heat shock proteins, Hsp70, and its implication in age-related diseases and cancer.